VAXART (VXRT) Stock News, May-Aug 2025

Vaxart (OTCQX: VXRT), a clinical-stage biotech company developing oral recombinant pill vaccines, has filed a preliminary proxy statement proposing a reverse stock split to regain Nasdaq compliance. The company will hold a Special Meeting of Stockholders on September 5, 2025, to vote on a reverse split ratio between 1-for-5 and 1-for-20.

Following trading suspension due to non-compliance with Nasdaq's minimum bid price requirements, Vaxart has appealed and scheduled a Nasdaq Hearings Panel meeting for August 14, 2025. The new proposal includes reducing authorized shares proportionally to the split ratio, incorporating feedback from stockholders after a previous failed vote in June 2025.

Vaxart (OTCQX: VXRT), a clinical-stage biotechnology company developing oral recombinant pill vaccines, announced its transition to trading on the OTCQX Best Market effective July 8, 2025. The company received a delisting notice from Nasdaq and has requested a hearing before the Nasdaq Hearings Panel, with its stock currently suspended from Nasdaq trading.

CEO Steven Lo emphasized the company's commitment to advancing their proprietary oral pill vaccine development while considering all options regarding their stock listing. Shareholders are not required to take any action regarding this trading transition.

Vaxart (VXRT) held its Annual Meeting of Stockholders with mixed voting results. Shareholders approved two key proposals: the election of six directors to serve until 2026 and the ratification of WithumSmith+Brown as the company's independent auditor. However, stockholders rejected two significant proposals: a reverse stock split amendment and the "say-on-pay" advisory vote on executive compensation. The company is currently evaluating its options regarding the rejected reverse split proposal. The final voting results will be reported in an upcoming Form 8-K filing with the SEC.

Vaxart (VXRT) announced positive Phase 1 clinical trial results for its second-generation oral norovirus vaccine, showing significantly stronger antibody responses compared to its first-generation technology. The trial involved 60 healthy volunteers and demonstrated a 141% increase in GI.1 and 94% increase in GII.4 norovirus blocking antibodies. The vaccine candidates were safe and well-tolerated across all dose groups. This advancement is significant as there is currently no approved vaccine for norovirus, which causes approximately 685 million infections globally annually and creates an economic burden of $60 billion worldwide. Pending partnership or funding, Vaxart plans to initiate a Phase 2b study in late 2025, followed by potential Phase 3 trials in 2026. The company's proprietary oral pill technology, enhanced in 2023-2024, aims to improve antigen protein expression and manufacturability.

Vaxart (NASDAQ: VXRT), a clinical-stage biotech company developing oral recombinant pill vaccines, announced it will host a conference call on June 11, 2025, at 8:30 AM ET to discuss topline results from its Phase I norovirus trial. The company will release the data before market open. Management will review the data and provide a trial update during the call. Investors can access the webcast through provided links and submit questions in advance to ir@vaxart.com. A replay will be available on Vaxart's website after the event.

Vaxart (NASDAQ: VXRT) has announced the adjournment of its 2025 annual stockholders meeting to June 13, 2025, at 8:30 a.m. PT. The adjournment affects all proposals outlined in the company's April 10 proxy statement. CEO Steven Lo reported positive discussions with major stockholders regarding the reverse stock split proposal (Proposal No. 2), with many indicating support following clarification of its importance for maintaining Nasdaq listing. Leading proxy advisory firms ISS and Glass Lewis have recommended stockholder support for the proposal. Stockholders of record as of March 26, 2025, can vote until June 12, 2025, at 11:59 p.m. ET. The reconvened meeting will be held virtually, accessible via the company's virtual shareholder meeting platform.

Vaxart (NASDAQ: VXRT), a clinical-stage biotech company specializing in oral recombinant pill vaccines, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management team will engage in a fireside chat on June 5, 2025, at 2:00 PM ET. The event will be accessible via live webcast on Vaxart's website, with a replay available for 30 days after the event. Investors seeking meetings with management during the conference should contact their Jefferies representative.

Vaxart (NASDAQ: VXRT) has released a video update from Founder and CSO Dr. Sean Tucker, urging stockholders to vote in favor of Proposal No. 2 for a reverse stock split. The proposal aims to help Vaxart regain compliance with Nasdaq's minimum bid price requirement. Stockholders of record as of March 26, 2025, must cast their votes by 11:59 p.m. Eastern Time on June 1, 2025. The company has also provided a fact sheet addressing common misconceptions about the reverse split proposal. Shareholders who previously voted against the proposal can change their vote, and assistance is available through Campaign Management, LLC.

Vaxart (VXRT) has provided detailed responses to stockholder questions ahead of its June 2, 2025 Annual Meeting, focusing on the crucial reverse stock split proposal. The company faces a June 30, 2025 Nasdaq compliance deadline and needs stockholder approval to maintain its listing. Key points include: the Board's commitment to a maximum 1-for-20 reverse split ratio (reduced from 1-for-50), plans to proportionally reduce authorized shares, and clarification on the $460.7 million BARDA Project NextGen award structure. The company has extended voting until June 1, 2025 at 11:59 p.m. ET. Management addressed concerns about dilution, short selling, and communication transparency, while emphasizing that the reverse split is currently the primary strategy for maintaining Nasdaq listing.